U.S. markets open in 1 hour 59 minutes
  • S&P Futures

    3,855.00
    +10.00 (+0.26%)
     
  • Dow Futures

    31,161.00
    +65.00 (+0.21%)
     
  • Nasdaq Futures

    13,354.00
    +59.75 (+0.45%)
     
  • Russell 2000 Futures

    2,165.60
    +7.90 (+0.37%)
     
  • Crude Oil

    53.04
    -0.27 (-0.51%)
     
  • Gold

    1,870.90
    +4.40 (+0.24%)
     
  • Silver

    25.97
    +0.20 (+0.77%)
     
  • EUR/USD

    1.2152
    +0.0037 (+0.30%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.24
    -2.00 (-8.61%)
     
  • GBP/USD

    1.3732
    +0.0077 (+0.56%)
     
  • USD/JPY

    103.3530
    -0.2170 (-0.21%)
     
  • BTC-USD

    31,867.22
    -1,634.88 (-4.88%)
     
  • CMC Crypto 200

    632.50
    -68.11 (-9.72%)
     
  • FTSE 100

    6,748.97
    +8.58 (+0.13%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

Neos Therapeutics, Inc.
·1 min read

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.

The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website at http://investors.neostx.com/ beginning Monday, January 11, 2021 at 6:00 a.m. ET. A replay of the webcast will be available on Neos’ website for 30 days.

About Neos Therapeutics
Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products. Neos markets Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD. Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions. Additional information about Neos is available at www.neostx.com.

CONTACTS:

Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com

Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah.mccabe@sternir.com